Holen Sie sich die Stockscreener-App
2.14
2.73%
-0.06
Schlusskurs vom Vortag:
$2.20
Offen:
$2.21
24-Stunden-Volumen:
135.02K
Relative Volume:
0.89
Marktkapitalisierung:
$109.04M
Einnahmen:
$96.63M
Nettoeinkommen (Verlust:
$-63.32M
KGV:
-1.0863
EPS:
-1.97
Netto-Cashflow:
$-54.55M
1W Leistung:
-0.93%
1M Leistung:
-23.57%
6M Leistung:
+8.91%
1J Leistung:
-52.97%
1-Tages-Spanne:
$2.11
$2.26
1-Wochen-Bereich:
$2.055
$2.35
52-Wochen-Spanne:
$1.88
$6.31
Akoya Biosciences Inc Stock (AKYA) Company Profile
Firmenname
Akoya Biosciences Inc
Sektor
Telefon
855.896.8401
Adresse
100 CAMPUS DRIVE, MARLBOROUGH
Vergleichen Sie AKYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
2.14 | 109.04M | 96.63M | -63.32M | -54.55M | -1.97 |
|
ISRG
Intuitive Surgical Inc
|
538.55 | 192.83B | 7.87B | 2.24B | 586.00M | 4.25 |
|
BDX
Becton Dickinson Co
|
221.98 | 64.77B | 20.18B | 1.73B | 3.07B | 5.51 |
|
ALC
Alcon Inc
|
88.23 | 43.75B | 9.76B | 1.16B | 665.00M | 0.72 |
|
RMD
Resmed Inc
|
249.33 | 36.84B | 4.81B | 1.11B | 1.35B | 6.16 |
|
WST
West Pharmaceutical Services Inc
|
323.32 | 23.33B | 2.88B | 499.60M | 321.60M | 7.41 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Herabstufung | Craig Hallum | Buy → Hold |
| 2024-08-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Buy |
| 2022-11-03 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-06-22 | Eingeleitet | BTIG Research | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-05-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Akoya Biosciences Inc Aktie (AKYA) Neueste Nachrichten
Piper Sandler Reiterates “Overweight” Rating for Akoya Biosciences (NASDAQ:AKYA) - Defense World
Akoya Biosciences stock target cut, rating held on recent earnings report - Investing.com Canada
Akoya Biosciences' (AKYA) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA) - Simply Wall St
Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Akoya Biosciences shares target cut, maintains buy rating on Q3 results - Investing.com
Craig-Hallum Downgrades Akoya Biosciences (AKYA) - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold - MSN
Akoya stock plunges 30% on outlook as Craig-Hallum cuts to hold (NASDAQ:AKYA) - Seeking Alpha
Akoya Biosciences (NASDAQ:AKYA) Price Target Cut to $3.50 by Analysts at Canaccord Genuity Group - MarketBeat
Akoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Craig Hallum - MarketBeat
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akoya Biosciences Shares Sink After FY24 Outlook Cut - MarketWatch
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 20.8% in October - MarketBeat
Akoya Biosciences, Inc. Revises Earnings Guidance for the Full Year 2024 - Marketscreener.com
Akoya: Q3 Earnings Snapshot - Darien Times
Akoya Biosciences Reports Q3 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Akoya Biosciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Akoya Biosciences earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt? - Simply Wall St
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Akoya Biosciences (AKYA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Precision for Medicine to Offer Spatial Biology Solutions Incorporating the PhenoCycler®-Fusion 2.0 System and the new Phenocode™ Discovery IO60 Panel from Akoya Biosciences - PR Newswire
Akoya Biosciences Unveils a New Era in Spatial Content - GlobeNewswire
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Akoya Biosciences, Inc. (NASDAQ:AKYA) Sees Significant Decrease in Short Interest - MarketBeat
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 - StockTitan
BTIG Downgrades Akoya Biosciences (AKYA) - MSN
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives $6.56 Consensus Price Target from Brokerages - MarketBeat
Akoya Biosciences (AKYA) Stock Price, News & Analysis - MarketBeat
Akoya Biosciences Inc (AKYA) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company - Simply Wall St
Akoya Biosciences joins UK cancer research initiative By Investing.com - Investing.com South Africa
Akoya Biosciences joins UK cancer research initiative - Investing.com India
Akoya’s Leading Spatial Proteomics Platforms Selected for - GlobeNewswire
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy - The Manila Times
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Uk-Based Manifest Consortium to Revolutionize Cancer Immunotherapy - Marketscreener.com
IPO Alert: Akoya Biosciences - RTTNews
Akoya Biosciences appoints new chairman By Investing.com - Investing.com South Africa
Akoya Biosciences Appoints Scott Mendel as Chairman of the Board of Directors - citybiz
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors - ForexTV.com
Akoya Biosciences appoints new chairman - Investing.com
Finanzdaten der Akoya Biosciences Inc-Aktie (AKYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akoya Biosciences Inc-Aktie (AKYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
239,368 |
| McKelligon Brian | President and CEO |
Mar 20 '24 |
Sale |
4.97 |
7,500 |
37,243 |
231,868 |
| McKelligon Brian | President and CEO |
Mar 13 '24 |
Sale |
4.94 |
7,500 |
37,035 |
224,368 |
| McKelligon Brian | President and CEO |
Dec 19 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
| McKelligon Brian | President and CEO |
Dec 19 '23 |
Sale |
4.48 |
7,500 |
33,566 |
152,563 |
| McKelligon Brian | President and CEO |
Dec 12 '23 |
Option Exercise |
0.30 |
7,500 |
2,272 |
160,063 |
| McKelligon Brian | President and CEO |
Dec 12 '23 |
Sale |
4.25 |
7,500 |
31,871 |
152,563 |
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):